Aclarion, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenues of $19,319 for the quarter, marking a 76% increase from $10,971 in the same period last year. For the first half of 2025, total revenues reached $38,309, an 82% increase compared to $21,085 in the first half of 2024. Despite this revenue growth, Aclarion reported a net loss of $1,600,757 for the quarter and $3,638,193 for the six-month period, reflecting losses of $2.75 and $9.09 per share, respectively.
The company’s operating expenses also rose, totaling $1,741,648 for the quarter, up from $1,123,238 in the prior year, driven by increased sales and marketing costs associated with the initiation of the Clarity trial and higher general and administrative expenses. The total operating expenses for the first half of 2025 were $3,229,084, compared to $2,389,184 in the same period of 2024. The increase in expenses was attributed to higher accruals for bonuses and increased consulting services.
Aclarion has made strategic moves to enhance its market position, including a public offering that raised approximately $14.6 million and two registered direct offerings totaling $5.2 million. The company also reported a significant increase in cash and cash equivalents, which rose to $12,850,657 as of June 30, 2025, compared to $1,182,687 at the end of the previous year. This increase in liquidity is expected to support the company’s operations and capital expenditures into the third quarter of 2026.
Operationally, Aclarion has focused on expanding its customer base, particularly in the UK market, where the volume of Nociscan reports sold has increased following favorable local coverage decisions. The company’s total assets grew to $14,754,520, up from $2,123,483 at the end of 2024, reflecting a substantial increase in stockholders' equity, which reached $14,190,098. The company’s employee headcount remains stable, with 582,371 shares of common stock outstanding as of August 14, 2025.
Looking ahead, Aclarion acknowledges the need for additional funding to continue its technology development and commercialization efforts. The company is actively managing its cash position and exploring long-term funding options to support its growth strategy. However, it cautions that future results may differ from current expectations due to various risks and uncertainties inherent in the healthcare technology sector.
About Aclarion, Inc.
Aclarion, Inc. develops non-invasive diagnostic technology using Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to identify painful intervertebral discs causing chronic low back and neck pain. Its flagship product, NOCISCAN®, enhances standard MRI scans by chemically analyzing disc tissue to guide treatment decisions, primarily for spine surgeons and imaging centers. The company’s software-driven platform aims to improve patient outcomes and reduce healthcare costs in the large, costly back pain market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.